BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed REGN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:57a7d42226e19971843b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:REGN P2 readout (est.): FERVENT-1
DESCRIPTION:A Study to Test the Safety\, Tolerability\, and Efficacy of an 
 Antibody\, REGN7999\, Injected Under the Skin for the Treatment of Iron Ov
 erload in Adult Participants With Non-Transfusion Dependent β-thalassemia
 \, Using MRI Scans to Measure Iron Levels in the Body\nNCT06421636 | PHASE
 2 | ACTIVE_NOT_RECRUITING | sponsor: Regeneron Pharmaceuticals\nPrimary co
 mpletion date (ESTIMATED)\; top-line results usually follow later.\nTicker
  REGN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT064216
 36\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06421636
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:a552f9d2e10ea592f95d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261229
DTEND;VALUE=DATE:20261230
SUMMARY:REGN P2 readout (est.): ASCEND-QW
DESCRIPTION:A Study to See How Safe and Effective Alirocumab is When Given 
 Weekly to Adult Participants Who Have Hypercholesterolemia\nNCT07477704 | 
 PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Regeneron Pharmaceuticals\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker REGN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0
 7477704\nScheduling/reference data from public records\; dates can move. N
 ot investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07477704
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:57c5db36b700a8808351@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:REGN P3 readout (est.): A Trial to See if the Combination of Fianli
 mab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Dela
 ying Melanoma From Coming Back After it Has Been Removed With Surgery
DESCRIPTION:A Trial to See if the Combination of Fianlimab With Cemiplimab 
 Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From C
 oming Back After it Has Been Removed With Surgery\nNCT05608291 | PHASE3 | 
 ACTIVE_NOT_RECRUITING | sponsor: Regeneron Pharmaceuticals\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker REG
 N (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05608291\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05608291
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f14de2a0e968ff92e7bd@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:REGN P2 readout (est.): ROXI-ATLAS
DESCRIPTION:Safety in Adult Participants With Atrial Fibrillation Who Are T
 reated With Anticoagulation\nNCT07175428 | PHASE2 | RECRUITING | sponsor: 
 Regeneron Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker REGN (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT07175428\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07175428
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9fce70662728520f072c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260819
DTEND;VALUE=DATE:20260820
SUMMARY:REGN APPROVAL: PASATRU
DESCRIPTION:Approved 2026-08-19: PASATRU (BLA761508 ORIG1)\nConfidence: con
 firmed\nTicker REGN (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761508\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761508
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:a6ed595d6cf202261326@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260422
DTEND;VALUE=DATE:20260423
SUMMARY:REGN APPROVAL: DUPIXENT
DESCRIPTION:Approved 2026-04-22: DUPIXENT (BLA761055 SUPPL74)\nConfidence: 
 confirmed\nTicker REGN (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761055
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:da5430eb41534fc7a015@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260402
DTEND;VALUE=DATE:20260403
SUMMARY:REGN APPROVAL: EYLEA HD
DESCRIPTION:Approved 2026-04-02: EYLEA HD (BLA761355 SUPPL5)\nConfidence: c
 onfirmed\nTicker REGN (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761355\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761355
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:94e56036d89fd5af43aa@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260224
SUMMARY:REGN APPROVAL: DUPIXENT
DESCRIPTION:Approved 2026-02-23: DUPIXENT (BLA761055 SUPPL75)\nConfidence: 
 confirmed\nTicker REGN (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761055\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761055
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:cb889ac5e84accfd1e09@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251120
SUMMARY:REGN APPROVAL: EYLEA HD
DESCRIPTION:Approved 2025-11-19: EYLEA HD (BLA761355 SUPPL10)\nConfidence: 
 confirmed\nTicker REGN (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761355\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761355
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
